Qiagen (NYSE: QGEN) and its partner Ellume are gearing up for the launch of the QIAreach SARS-CoV-2 antigen test, which can reportedly process samples in 2–15 minutes. Qiagen notes that the test can process up to 30 swab samples per hour while supporting parallel processing of antibody tests. The companies have submitted the test for […]
Qiagen N.V.
MedTech 100 roundup: Up-and-down week for industry
Medtech stocks highlighted the topsy-turvy nature of the market last week, but ultimately finished the seven days nearly unchanged. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.77 points at the end of last week (Aug. 14). Overall, medtech stocks saw a 0.13% increase from the […]
BREAKING: Thermo Fisher drops bid for Qiagen
Thermo Fisher Scientific (NYSE:TMO) announced today that its offer to acquire Qiagen (NYSE:QGEN) in an $11.5 billion deal has lapsed. According to a news release, more than 107.5 million shares of Qiagen (47.02% of the issued and outstanding ordinary shares for the company) were validly tendered into the offer by the end of the acceptance period on […]
AdvaMed unveils COVID-19 diagnostic supply registry
AdvaMed announced today that it created a comprehensive national COVID-19 diagnostic supply registry to aid state and federal pandemic responses. According to a news release, AdvaMed is launching the registry in partnership with 13 commercial diagnostics manufacturers: Abbott (NYSE:ABT), Becton Dickinson (NYSE:BDX), bioMérieux, Bio-Rad Laboratories (NYSE:BIO), Beckman Coulter, Cepheid, Hologic (NSDQ:HOLX), Ortho Clinical Diagnostics, Qiagen (NYSE:QGEN), Roche Diagnostics, Sekisui Diagnostics, […]
Thermo Fisher boosts offer for Qiagen
Thermo Fisher Scientific (NYSE:TMO) has boosted its per-share offer price for Qiagen (NYSE:QGEN) after some shareholders reportedly balked at the original offer for the sample and assay tech company. Thermo Fisher Scientific is now offering €43 per QGEN share, up from the previous €39 per share offer, at the same time that the companies have agreed to […]
Qiagen COVID-19 diagnostic granted emergency authorization
The FDA granted an emergency use authorization to Qiagen (NYSE:QGEN) for a diagnostic test that the company said can differentiate among COVID-19 and 20 other respiratory diseases that cause similar symptoms, the company said today. The SARS-CoV-2 Panel test works in about an hour, according to Netherlands-based Qiagen. It is a multiplexed nucleic acid test […]
Thermo Fisher lines up financing for Qiagen buy
Thermo Fisher Scientific (NYSE:TMO) confirmed in a prospectus supplement that it is in part financing its $11.5 billion purchase of Qiagen (NYSE:QGEN) with an offering worth $2.2 billion. The offering includes $1.1 billion in 4.133% senior notes due in 2025 and another $1.1 billion in 4.497% senior notes due in 2030. Thermo Fisher said in its prospectus […]
ThermoFisher to buy Qiagen for $11.5 billion
Thermo Fisher Scientific (NYSE:TMO) and Qiagen (NYSE:QGEN) announced today that their boards have unanimously approved Thermo Fisher’s proposal to acquire Qiagen for approximately $11.5 billion. The proposal is that Thermo Fisher will acquire Qiagen for €39 per share in cash, or $43.53. That price represents a premium of approximately 23% of the closing price of Qiagen’s common […]
BD sues NeuMoDx over patents for diagnostic device
Becton Dickinson (NYSE:BDX) and subsidiaries HandyLab and GeneOhm Sciences Canada have filed a lawsuit against diagnostics company NeuMoDx, claiming patent infringement. BD acquired small diagnostics company HandyLab (Ann Arbor, Mich.) in 2009 for $275 million. HandyLab was developing bench-top devices for fast and early detection of diseases, according to the complaint, filed in U.S. District […]
Qiagen wins FDA nod for point-of-care PartoSure test
Qiagen (NYSE:QGEN) today touted the FDA’s approval of its PartoSure diagnostic test, designed to assess the risk of spontaneous preterm birth in patients with symptoms of preterm labor. The non-invasive strip test detects placental alpha microglobulin-1 and can provide results in less than five minutes, according to Germany-based Qiagen. Get the full story at our sister […]
Qiagen launches liquid biopsy tests for lung, prostate cancer
Qiagen (NYSE:QGEN) today launched two liquid biopsy panels designed to evaluate circulating tumor cells isolated from a patient’s blood samples. The company’s lung and prostate cancer diagnostic tests will be introduced at the annual meeting of the American Association for Cancer Research in Chicago, according to Qiagen. Get the full story at our sister site, Drug […]
